US Patent 5,149,694: Scope, Claims, and US Patent Landscape for Topical Tobramycin + Dexamethasone in Ophthalmic Inflammation/Infection

What does US 5,149,694 claim, and what is the operative scope?

US 5,149,694 is directed to a method of treatment for ophthalmic inflammation and infection using a single topical ophthalmic composition containing:

Dexamethasone in an anti-inflammatory effective amount
Tobramycin in an anti-infective effective amount
A pharmaceutically acceptable carrier
Administered topically to the affected eye of a human host

The independent claim is method-based, not product-based: it requires administration of the defined drug combination in a defined therapeutic purpose setting (inflammation and infection in the eye), using a topical ophthalmic formulation.

Claim set provided (verbatim substance from prompt)

Claim 1 A method of treating ophthalmic inflammation and infection comprising:

administering topically to the affected eye of a human host
a therapeutically effective amount of an ophthalmic pharmaceutical composition comprising:
- an anti-inflammatory effective amount of dexamethasone
- an anti-infective effective amount of tobramycin
- a pharmaceutically acceptable carrier.

Claim 2 (composition and ratio limit) A method according to claim 1 wherein:

combined concentration of tobramycin + dexamethasone is 0.01 to 2.0% by weight
the ratio of tobramycin:dexamethasone is 0.1:1.0 to 10.0:1.0.

Claim 3 (specific concentrations) A method according to claim 1 wherein:

tobramycin 0.3% by weight
dexamethasone 0.1% by weight.

What is the claim construction logic for enforceable boundaries?

1) “Method of treating ophthalmic inflammation and infection”

This claim language typically narrows the infringement hook to scenarios where the intended use or clinical effect involves both:

inflammation and
infection in the ophthalmic context.

Practically, this matters because a product labeled or used solely for inflammation (steroid alone) or solely for infection (antibiotic alone) does not meet the method claim’s treatment purpose unless the claim is satisfied through the actual administered combination and patient condition.

2) “Administering topically to the affected eye of a human host”

This is a direct limitation:

route: topical ophthalmic
target: affected eye
patient: human host

It excludes systemic administration and excludes non-human hosts on the face of the claims.

3) “Therapeutically effective amount” of the composition

Both components are functionally defined:

dexamethasone: anti-inflammatory effective amount
tobramycin: anti-infective effective amount

Function-based dosing language creates scope that tracks therapeutic effect rather than strict mg amounts, but claims 2 and 3 add objective concentration guardrails. Claim 2 sets an outer band on combined concentration and ratio; claim 3 sets a fixed concentration pair.

4) “Pharmaceutically acceptable carrier”

This is a standard formulation element. It typically does not materially narrow scope unless a competitor uses a materially different carrier concept argued not to be “pharmaceutically acceptable,” which is usually not a high barrier in enforcement for ophthalmic formulations.

5) Concentration and ratio constraints in dependent claims

Claim 2 creates a definable infringement region even for variable dosing:
- total concentration (tobramycin + dexamethasone) must be 0.01 to 2.0% by weight
- tobramycin:dexamethasone ratio must be 0.1:1.0 to 10.0:1.0
Claim 3 is a bright-line embodiment:
- tobramycin 0.3% w/w
- dexamethasone 0.1% w/w
- ratio implied by claim 3 is 3.0:1.0, which falls inside claim 2’s ratio band.

How broad is the independent claim compared with the dependent concentration limits?

Independent claim 1 is broad on:

purpose (ophthalmic inflammation and infection)
route (topical to the affected eye)
functional dosing (therapeutically effective; anti-inflammatory effective; anti-infective effective)

Dependent claim 2 narrows by forcing objective composition constraints:

total combined actives: 0.01 to 2.0% w/w
ratio: 0.1:1.0 to 10.0:1.0

Dependent claim 3 narrows further to a specific marketed-style pairing:

0.3% tobramycin + 0.1% dexamethasone

From an infringement standpoint:

A product matching claim 3 automatically matches claim 2’s numeric conditions.
A product matching claim 2’s band still does not automatically meet claim 1 unless it is used in the claimed “method” setting (ophthalmic inflammation and infection in a human host, via topical administration).

What does this imply for product mapping and “design-around” strategy?

Product mapping checklist against the claim set

To land in the claimed scope, an accused method/product combination generally needs to satisfy:

Topical ophthalmic administration to a human
Treatment of conditions characterized as both inflammation and infection in the eye
Composition contains both:
- dexamethasone (anti-inflammatory effective amount)
- tobramycin (anti-infective effective amount)
- acceptable carrier
If litigating under dependent claims:
- claim 2: total combined actives 0.01 to 2.0% w/w and ratio 0.1:1.0 to 10.0:1.0
- claim 3: exact 0.3% tobramycin + 0.1% dexamethasone

Likely boundaries for avoidance (within the claim text)

If dexamethasone is reduced to below a ratio threshold relative to tobramycin, it may fall outside claim 2’s ratio band.
If the combined concentration falls outside 0.01 to 2.0% w/w, it fails claim 2’s numeric constraint (and could become more difficult for claim 1 because functionally effective dosing might still be argued, depending on evidence).
If either active is omitted, the composition fails at the face of claim 1.

Where does US 5,149,694 sit in the US patent landscape for steroid-antibiotic ophthalmic combinations?

Structural landscape: claim type and likely competitive set

US 5,149,694 is a combination-use method built around a classic steroid-antibiotic ophthalmic pairing:

dexamethasone (steroid)
tobramycin (aminoglycoside antibiotic)

In the US market and patent practice, this area typically includes:

branded and generic fixed combinations using steroid-antibiotic combinations for ocular inflammation with infection or infection risk
reformulations that vary carrier systems and possibly concentrations
method-of-use claims (and sometimes product claims) keyed to “inflammation and infection” language
later filings that attempt to occupy adjacent concentration ratios, dosing regimens, or narrower indication wording

Because the claim here is already concentrated on the combination and specific concentration pair (claim 3), subsequent patentability efforts commonly move toward:

different ratios/concentration ranges outside claim 2
alternative corticosteroids (not dexamethasone)
alternative antibiotic components (not tobramycin)
non-overlapping claims tied to different disease wording or different administration regimens
device-based or preservative system changes when product claims exist (though this patent’s claims as provided do not pivot on preservative system language)

Competitive implication of claim 2 and claim 3 numeric guardrails

For entrants evaluating freedom-to-operate, claims 2 and 3 create clear numeric checkpoints:

A formulation with 0.3%/0.1% (tobramycin/dexamethasone) fits claim 3.
A formulation with tobramycin:dexamethasone ratios in 0.1:1.0 to 10.0:1.0 and combined concentration 0.01 to 2.0% fits claim 2, assuming the method-of-use elements are met.

This design makes it harder to “slide” concentrations slightly without crossing numeric boundaries, particularly if the intended steroid-to-antibiotic balance falls into conventional ranges used in ophthalmic combo products.

How can the scope be summarized into enforceable “infringement predicates”?

Minimum predicates for Claim 1

Predicate	Text anchor	Practical meaning
Route and site	“administering topically to the affected eye”	Ophthalmic topical administration only
Patient class	“human host”	Not limited to age group, but limited to humans
Treatment context	“ophthalmic inflammation and infection”	Both inflammation and infection elements must be in play
Therapeutically effective composition	“therapeutically effective amount”	Dosing must be plausibly therapeutic; evidence often required in practice
Composition content	“comprising… dexamethasone… tobramycin… carrier”	Must contain both actives with effective amounts

Additional predicates for Claim 2

Predicate	Numeric constraint
Combined concentration	tobramycin + dexamethasone = 0.01 to 2.0% by weight
Ratio constraint	tobramycin:dexamethasone = 0.1:1.0 to 10.0:1.0

Additional predicates for Claim 3

Predicate	Exact numeric constraint
Tobramycin	0.3% by weight
Dexamethasone	0.1% by weight
Ratio implied	3.0:1.0 (within claim 2)

What is the “patent landscape” consequence of a method claim like this versus a composition claim?

A method claim can be implicated by:

clinician behavior and label-driven use patterns
marketing and instructions that induce the claimed treatment
evidence tied to what was prescribed and administered

In practice, enforcement for method-of-treatment claims often hinges on:

whether the accused product is administered in the claimed combination
whether the treated condition matches “ophthalmic inflammation and infection”
whether dosing in practice satisfies effective amounts, and whether dependent numeric claims are met

A product-claim landscape may allow easier market-level mapping. A method-claim landscape can create more uncertainty because it is tied to real-world administration and treatment purpose, even when the formulation is identical.

Key Takeaways

US 5,149,694 claims a topical human method to treat ophthalmic inflammation and infection using a single ophthalmic composition with dexamethasone + tobramycin and a pharmaceutically acceptable carrier.
Claim 1 is broad on functional dosing and treatment context; it requires the steroid and antibiotic combination in an effective amount and topical administration to the affected eye.
Claim 2 narrows scope with objective numeric boundaries: total actives 0.01 to 2.0% w/w and tobramycin:dexamethasone ratio 0.1:1.0 to 10.0:1.0.
Claim 3 is a bright-line formulation: tobramycin 0.3% w/w + dexamethasone 0.1% w/w, which sits inside claim 2.
For freedom-to-operate assessments in this class, the numeric constraints and the “inflammation and infection” use framing are the main enforceable levers.

FAQs

1) Does US 5,149,694 protect a product formulation or a treatment method?
It protects a method of treatment (claim 1 and dependents), based on administering the combination topically to the affected eye of a human for ophthalmic inflammation and infection.

2) What concentration pair is explicitly covered?
Claim 3 covers tobramycin 0.3% w/w with dexamethasone 0.1% w/w.

3) What numeric range of steroid-to-antibiotic ratio is covered (dependent claim 2)?
Claim 2 covers tobramycin:dexamethasone ratios from 0.1:1.0 to 10.0:1.0.

4) What is the covered total active concentration range (dependent claim 2)?
Claim 2 covers combined tobramycin + dexamethasone at 0.01% to 2.0% by weight.

5) Can a formulation with different carriers avoid infringement?
Carrier differences do not appear to avoid claim scope unless the carrier is not “pharmaceutically acceptable.” The core constraints are the actives, their effective amounts, the topical ophthalmic route, and the treatment context.

References

[1] US Patent 5,149,694 (claims as provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	122564	⤷ Start Trial
Australia	3347689	⤷ Start Trial
Australia	606515	⤷ Start Trial
Canada	1338554	⤷ Start Trial
Germany	365613	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,149,694

Summary for Patent: 5,149,694